ArticleCritical care (London, England)2025
ORAKLE: Optimal Risk prediction for mAke30 in patients with sepsis associated AKI using deep LEarning.
Article in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biomarker-guided immunomodulation in septic shock: navigating controversies and therapeutic implications for Critical Care.Critical care (London, England) · 2026Article
- Dynamic prognostic nutritional index and 28-day mortality in sepsis: a joint modeling analysis.Nutrition & metabolism · 2026Article
- Artificial intelligence in emergency medicine critical care.Clinical and experimental emergency medicine · 2026Article
- Biomarker-driven risk stratification and early intervention in acute kidney injury: a comprehensive review from early warning to clinical response.Frontiers in medicine · 2026Review
- Personalized Fluid Management in Patients With Sepsis and Acute Kidney Injury: A Causal Machine Learning Approach.Critical care explorations · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMajor Adverse Kidney Events within 30 days (MAKE30) is an important patient-centered outcome for assessing the impact of acute kidney injury (AKI). Existing prediction models for MAKE30 are static and overlook dynamic changes in clinical status. We introduce ORAKLE, a novel deep-learning model that utilizes evolving time-series data to predict MAKE30, enabling personalized, patient-centered approaches to AKI management and outcome improvement.
methodsWe conducted a retrospective study using three publicly available critical care databases: MIMIC-IV as the development cohort, and SiCdb and eICU-CRD as external validation cohorts. Patients with sepsis-3 criteria who developed AKI within 48 h of intensive care unit admission were identified. Our primary outcome was MAKE30, defined as a composite of death, new dialysis or persistent kidney dysfunction within 30 days of ICU admission. We developed ORAKLE using Dynamic DeepHit framework for time-series survival analysis and its performance against Cox and XGBoost models. We further assessed model calibration using Brier score.
resultsWe analyzed 16,671 patients from MIMIC-IV, 2665 from SICdb, and 11,447 from eICU-CRD. ORAKLE outperformed the XGBoost and Cox models in predicting MAKE30, achieving AUROCs of 0.84 (95% CI: 0.83-0.86) vs. 0.81 (95% CI: 0.79-0.83) vs. 0.80 (95% CI: 0.78-0.82) in MIMIC-IV internal test set, 0.83 (95% CI: 0.81-0.85) vs. 0.80 (95% CI: 0.78-0.83) vs. 0.79 (95% CI: 0.77-0.81) in SICdb, and 0.85 (95% CI: 0.84-0.85) vs. 0.83 (95% CI: 0.83-0.84) vs. 0.81 (95% CI: 0.80-0.82) in eICU-CRD. The AUPRC values for ORAKLE were also significantly better than that of XGBoost and Cox models. The Brier score for ORAKLE was 0.21 across the internal test set, SICdb, and eICU-CRD, suggesting good calibration.
conclusionsORAKLE is a robust deep-learning model for predicting MAKE30 in critically ill patients with AKI that utilizes evolving time series data. By incorporating dynamically changing time series features, the model captures the evolving nature of kidney injury, treatment effects, and patient trajectories more accurately. This innovation facilitates tailored risk assessments and identifies varying treatment responses, laying the groundwork for more personalized and effective management approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.